Oxycodone Pediatric Dose — Pain Management
Oxycodone is a semi-synthetic opioid analgesic that exerts its analgesic effect through agonism at mu-opioid receptors in the central and peripheral nervous system. It is used in pediatric patients for the management of moderate-to-severe pain requiring opioid therapy. Immediate-release oral formulations are the primary preparation utilized in children, with dosing individualized by weight.
Pediatric Dosing
For pediatric patients, oxycodone immediate-release oral preparations are dosed on a per-kilogram basis:
- Immediate-release (weight-based, pediatric): 0.05–0.15 mg/kg per dose PO every 4 hours or every 6 hours PRN
- Initial adult dose (patients >50 kg): 5 mg/dose PO every 4 hours or every 6 hours PRN (fixed dosing, not weight-based)
- Extended-release formulation (adults): Start with 10 mg every 12 hours — not indicated for weight-based pediatric dosing per this reference
Worked example: For a 20 kg child using immediate-release oxycodone: 20 kg × 0.05 mg/kg = 1 mg (low end) to 20 kg × 0.15 mg/kg = 3 mg per dose PO every 4–6 hours PRN. Consult institutional protocol for maximum single-dose limits.
Indications and Clinical Context
Oxycodone immediate-release oral formulations are indicated for the management of moderate-to-severe pain in pediatric patients when non-opioid analgesics have proven inadequate. Common clinical contexts include post-operative pain, significant musculoskeletal injury, or other acute pain states requiring short-term opioid therapy. Opioid analgesics should be prescribed as part of a multimodal pain management strategy whenever feasible.
In patients weighing more than 50 kg, fixed adult dosing (5 mg every 4–6 hours PRN) is applied rather than weight-based calculations. Extended-release oxycodone formulations are referenced for adult initiation only and should not be extrapolated to pediatric weight-based dosing without explicit institutional or specialist guidance.
Administration and Monitoring
Oxycodone is administered by the oral (PO) route. Immediate-release preparations are appropriate for intermittent PRN dosing schedules (every 4 or every 6 hours). Clinicians should assess pain scores before each PRN dose and reassess response within an appropriate interval post-administration.
- Route: Oral (PO) only per this reference; consult institutional protocol for alternative routes
- Adverse effects to monitor: Respiratory depression, sedation, nausea, vomiting, constipation, and pruritus
- Key contraindications: Significant respiratory depression, paralytic ileus, known hypersensitivity to oxycodone
- Opioid safety: Ensure availability of naloxone for reversal; apply appropriate monitoring per institutional opioid safety policies
- Extended-release caution: Extended-release formulations carry a high risk of misuse and overdose; use is defined here for adult initiation only
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.